Clinical Trials
17 results for Bladder Cancer
Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
- Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
- Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
- Study ID: NCT01050504
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
- Condition: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
- Study ID: NCT00872495
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum
- Condition: Stage IV Bladder Urothelial Carcinoma
- Intervention: Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Procedure: Positron Emission Tomography, Biological: Recombinant EphB4-HSA Fusion Protein
- Study ID: NCT02717156
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
- Condition: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
- Intervention: Drug: Gemcitabine Hydrochloride, Drug: Cisplatin, Biological: Pegfilgrastim, Procedure: Conventional Surgery, Procedure: Radical Cystectomy, Other: Chemoradiotherapy
- Study ID: NCT03609216
Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"
- Condition: Upper Tract Urothelial Carcinoma
- Intervention: Procedure: RNU, Drug: Gemcitabine/Cisplatin, Drug: M-VAC Protocol
- Study ID: NCT02969083
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
- Condition: Urothelial Carcinoma
- Study ID: NCT03547973
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
- Condition: Bladder Cancer, Bladder Cancer, Metastatic
- Intervention: Drug: Atezolizumab
- Study ID: NCT04138628
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
- Condition: Renal Pelvis and Ureter Urothelial Carcinoma
- Study ID: NCT04628767
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)
- Condition: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
- Study ID: NCT05544552
An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations
- Condition: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Study ID: NCT05614739
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
- Condition: Ovarian Epithelial Cancer, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Triple Negative Breast Cancer, Bladder Cancer
- Intervention: Drug: SKB264
- Study ID: NCT04152499
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)
- Condition: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer
- Study ID: NCT05489211
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors
- Condition: Advanced Solid Tumors
- Study ID: NCT05941507
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
- Condition: Advanced Solid Tumor, Urinary Bladder Neoplasm, Pancreatic Neoplasms, Triple Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasm, Esophageal Neoplasms, Ovarian Neoplasm
- Study ID: NCT04561362
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- Condition: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamo
- Study ID: NCT06238479
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
- Condition: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamo
- Study ID: NCT06465069
A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
- Condition: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
- Study ID: NCT06036121